LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

LLY

712.25

-4.67%↓

JNJ

152.87

-0.45%↓

ABBV

181.75

-1.09%↓

NVO

66.83

-2.81%↓

UNH

297.81

-2.36%↓

Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

32.54 -0.12

Overview

Share price change

24h

Current

Min

32

Max

33.01

Key metrics

By Trading Economics

Income

33M

-48M

Sales

-2.6M

106M

EPS

-0.45

Profit margin

-45.487

Employees

1,869

EBITDA

19M

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+61.35% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

194M

3.6B

Previous open

32.66

Previous close

32.54

News Sentiment

By Acuity

23%

77%

49 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 maj 2025, 23:25 UTC

Hot Stocks

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 maj 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 maj 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 maj 2025, 21:01 UTC

Major Market Movers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 maj 2025, 20:51 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 maj 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 maj 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 maj 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 maj 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 maj 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 maj 2025, 23:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 maj 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 maj 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 maj 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 maj 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 maj 2025, 23:28 UTC

Earnings

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 maj 2025, 23:27 UTC

Earnings

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 maj 2025, 23:26 UTC

Earnings

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 maj 2025, 23:26 UTC

Earnings

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 maj 2025, 23:26 UTC

Earnings

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 maj 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 maj 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 maj 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 maj 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 maj 2025, 21:42 UTC

Top News
Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 maj 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 maj 2025, 21:07 UTC

Top News

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 maj 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 maj 2025, 20:59 UTC

Top News

Walmart to Cut 1,500 Jobs -- WSJ

21 maj 2025, 20:52 UTC

Earnings

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

61.35% upside

12 Months Forecast

Average 52.65 USD  61.35%

High 73 USD

Low 32.6 USD

Based on 6 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

49 / 382 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.